

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Cytochrome P450 2D6 (CYP2D6); ATP-binding cassette sub-family C member 2 (ABCC2)	Genotyping studies identified CYP2D6 and ABCC2 polymorphisms that could help predict responsiveness to tamoxifen therapy for breast cancer. In 282 tamoxifen patients with estrogen receptor- or progesterone receptor-positive breast cancer, as compared with matched controls, genotypic variants of the <i>CYP2D6</i> and <i>ABCC2</i> genes were associated with recurrence-free survival. In an analysis of plasma samples from 98 additional patients receiving 20 mg/day of tamoxifen, <i>CYP2D6</i> variants were also associated with increased tamoxifen metabolism. Next steps include further retrospective and prospective studies to confirm the results.	Findings unpatented; unavailable for licensing	Kiyotani, K. <i>et al. J. Clin. Oncol.</i> ; published online Feb. 1, 2010; doi:10.1200/JCO.2009.25.7246 Contact: Yusuke Nakamura, Institute of Medical Science, The University of Tokyo, Tokyo, Japan e-mail: yusuke@ims.u-tokyo.ac.jp
		SciBX 3(7); doi:10.1038/scibx.2010.210 Published online Feb. 18, 2010		